MeiraGTx Holdings PLC (OQ:MGTX)

Apr 18, 2024 04:30 pm ET
MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company gave an oral presentation at the American Academy of Oral Medicine Annual Conference, being held from April 16-20, 2024,...
Mar 14, 2024 08:30 am ET
MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial and operational results for the fourth quarter and full-year ended December 31, 2023, and provided a corporate update....
Feb 13, 2024 08:00 am ET
MeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the achievement of the first milestone under the asset purchase agreement the Company entered into with Janssen Pharmaceuticals,...
Dec 21, 2023 08:31 am ET
Thinking about buying stock in Hookipa Pharma, Riot Platforms, Celestica, Mesoblast, or MeiraGTx?
NEW YORK, Dec. 21, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HOOK, RIOT, CLS, MESO, and MGTX.
Dec 21, 2023 07:00 am ET
MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced an asset purchase agreement with Janssen Pharmaceuticals, Inc. (J&J), a Johnson & Johnson company, for the remaining interests in...
Nov 21, 2023 04:30 pm ET
MeiraGTx to Participate in Upcoming Investor Conferences
MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences: 6th...
Nov 14, 2023 08:00 am ET
MeiraGTx Announces Third Quarter 2023 Financial and Operational Results
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial and operational results for the third quarter ended September 30, 2023, and provided a corporate update. “We are...
Oct 31, 2023 09:31 am ET
Thinking about buying stock in T2 Biosystems, Cybin, Alphabet Inc, Archer Aviation, or MeiraGTx Holdings?
NEW YORK, Oct. 31, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TTOO, CYBN, GOOGL, ACHR, and MGTX.
Oct 30, 2023 07:30 am ET
MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced strategic updates including that Sanofi has made a $30 million strategic investment in the Company through the purchase of 4.0...
Oct 24, 2023 08:30 am ET
MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company will exhibit eight posters and deliver one oral presentation at the European Society of Gene and Cell Therapy (ESGCT)...
Aug 10, 2023 08:00 am ET
MeiraGTx Reports Second Quarter 2023 Financial and Operational Results
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial and operational results for the second quarter ended June 30, 2023, and provided a corporate update. “Progress across our...
Aug 01, 2023 09:10 am ET
MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced a poster presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-oncology, which is being...
Jul 19, 2023 08:30 am ET
MeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has Received Commercial MIA Authorization for QC Testing
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that after a successful inspection by the Irish Health Products Regulatory Authority (HPRA), it has received a Commercial...
Jun 27, 2023 07:30 am ET
MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced positive clinical data from the completed Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 radiation-induced...
Jun 22, 2023 04:01 pm ET
MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company’s Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade
MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference call and webcast to present an update on the Company’s AAV-hAQP1 clinical program for the treatment of...
May 16, 2023 09:00 am ET
MeiraGTx Announces the Presentation of Nine Posters at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company will exhibit nine poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting,...
May 11, 2023 08:00 am ET
MeiraGTx Reports First Quarter 2023 Financial and Operational Results
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial and operational results for the first quarter ended March 31, 2023, and provided a corporate update. “We are off to a...
May 03, 2023 08:30 am ET
MeiraGTx Announces $60 Million Private Placement of Ordinary Shares
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has agreed to sell approximately 10.7 million ordinary shares at a price of $5.75 per share. MeiraGTx anticipates aggregate...
Apr 21, 2023 08:30 am ET
MeiraGTx Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced two abstract presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting. The first...
Apr 20, 2023 05:00 pm ET
MeiraGTx to Participate in Upcoming Investor Conferences
MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences:...
Mar 14, 2023 08:00 am ET
MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial and operational results for the fourth quarter and full-year ended December 31, 2022, and provided a corporate update....
Dec 13, 2022 07:30 am ET
MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced positive clinical data from the ongoing Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 radiation-induced xerostomia...
Dec 08, 2022 04:30 pm ET
MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022
MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference call and webcast to present clinical data from the Company’s AAV-hAQP1 Phase 1 AQUAx clinical trial for...
Nov 22, 2022 04:30 pm ET
MeiraGTx to Participate in Upcoming Investor Conferences
MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences: Piper...
Nov 10, 2022 08:00 am ET
MeiraGTx Reports Third Quarter 2022 Financial and Operational Results and Receives $25 Million Investment from Johnson & Johnson Innovation - JJDC, Inc.
Now Dosing Patients in Phase 1 Trial Evaluating AAV-GAD Gene Therapy for Parkinson’s Disease -- Received $25.0 Million Investment from Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”), the Investment Arm of Johnson and Johnson -- Company to...
Oct 04, 2022 08:00 am ET
MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company will exhibit 15 poster presentations at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress,...
Oct 01, 2022 10:00 am ET
Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigm
MeiraGTx Holdings plc (Nasdaq:MGTX), a vertically integrated, clinical-stage gene therapy company, announced today the primary results from the Phase 1/2 study evaluating the investigational gene therapy botaretigene sparoparvovec (formerly...
Sep 16, 2022 02:00 am ET
MeiraGTx’s Industry-Leading Gene Therapy Manufacturing Facility in Shannon, Ireland Formally Introduced by Head of Irish Government
MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, will today formally unveil its GMP manufacturing facility in Shannon, Ireland, with the Head of Irish Government, Micheál Martin, in attendance....
Sep 08, 2022 04:30 pm ET
MeiraGTx to Participate in Upcoming Investor Conferences
MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences: Morgan...
Aug 11, 2022 08:30 am ET
MeiraGTx Reports Second Quarter 2022 Financial and Operational Results
Financing Secured by Manufacturing Facilities Extends Cash Runway to Fourth Quarter 2024 LONDON and NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage gene therapy company,...
Aug 03, 2022 08:00 am ET
MeiraGTx Announces Financing Agreement with Perceptive Advisors for Up to $100 Million Secured by Manufacturing Facilities
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage gene therapy company, today announced a term loan agreement with affiliates of Perceptive Advisors for up to $100 million, including $75 million upon closing. “Access to...
Jun 28, 2022 07:00 am ET
MeiraGTx Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision in X-Linked Retinitis Pigmentosa Patients treated
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced top-line data from the Phase 1/2 clinical study MGT009 (NCT03252847) of botaretigene sparoparvovec (formerly referred to as...
May 12, 2022 08:00 am ET
MeiraGTx Reports First Quarter 2022 Financial and Operational Results
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the first quarter ended March 31, 2022 and provided an update on recent progress. “During the first quarter...
May 04, 2022 04:01 pm ET
MeiraGTx Presents Clinical Data on Botaretigene Sparoparvovec for the Treatment of X-Linked Retinitis Pigmentosa at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting
MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage gene therapy company, today announced that additional clinical data from the Phase 1/2 trial of botaretigene sparoparvovec for the treatment of X-linked Retinitis...
Apr 27, 2022 08:00 am ET
MeiraGTx Appoints Debra Yu, MD to Board of Directors
MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Dr. Debra Yu to its Board of Directors. Dr. Yu currently serves as President and Chief Strategy Officer of...
Apr 19, 2022 04:30 pm ET
MeiraGTx to Participate in Upcoming Investor and Scientific Conferences
MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following investor and scientific...
Mar 10, 2022 08:00 am ET
MeiraGTx Reports Fourth Quarter and Full Year 2021 Financial and Operational Results
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial and operational results for the fourth quarter and full-year ended December 31, 2021, and provided a corporate update....
Jan 27, 2022 08:30 am ET
MeiraGTx Receives Clinical Development Milestone Payment from Janssen
MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has received a $30 million payment from Janssen Pharmaceuticals, Inc. (Janssen), part of the Janssen Pharmaceutical Companies...
Dec 14, 2021 04:30 pm ET
MeiraGTx to Host a Virtual Research and Development Day on Gene Regulation
MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, will host a virtual R&D Day via webcast and conference call on Wednesday, December 15, 2021, from 10:00 a.m. to 12:00 p.m. ET highlighting the...
Dec 07, 2021 07:00 am ET
MeiraGTx Announces Positive Preliminary Data from the AQUAx Phase 1 Clinical Trial of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced positive preliminary data from the ongoing Phase 1 AQUAx trial of AAV-hAQP1 for the treatment of grade 2/3 radiation-induced...
Nov 29, 2021 04:30 pm ET
MeiraGTx to Provide a Xerostomia Clinical Program Update and Host a Virtual Research and Development Day on Gene Regulation
MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference call and webcast to provide an update on the Company’s AAV-hAQP1 Phase 1 AQUAx clinical trial for the...
Nov 10, 2021 08:00 am ET
MeiraGTx Reports Third Quarter 2021 Financial and Operational Results
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the third quarter ended September 30, 2021 and provided an update on recent progress. During the quarter,...
Nov 09, 2021 04:30 pm ET
MeiraGTx to Participate in Upcoming Virtual Investor Conferences
MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following virtual investor conferences:...
Oct 19, 2021 08:30 am ET
MeiraGTx Announces the Presentation of Two Novel Inherited Retinal Disease (IRD) Programs and Riboswitch Gene Regulation Platform at the European Society of Gene and Cell Therapy (ESGCT) 2021 Annual C
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced three poster presentations at the European Society of Gene and Cell Therapy (ESGCT) 2021 Annual Congress. Two pre-clinical programs...
Sep 28, 2021 04:30 pm ET
MeiraGTx to Present at the Chardan 5th Annual Genetic Medicines Conference
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the virtual Chardan 5th Annual Genetic...
Sep 09, 2021 08:30 am ET
MeiraGTx Announces Data at EURETINA 2021 Virtual Meeting Demonstrating Reversal of Disease Progression Following Treatment with AAV5-RPGR in X-Linked Retinitis Pigmentosa
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced new data from subjects treated in the Phase 1/2 dose escalation phase of Study MGT009 indicating AAV5-RPGR, an investigational gene...
Aug 11, 2021 08:00 am ET
MeiraGTx Reports Second Quarter 2021 Financial and Operational Results
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the second quarter ended June 30, 2021 and provided an update on recent progress. “As we move into the second...
May 11, 2021 08:00 am ET
MeiraGTx Reports First Quarter 2021 Financial and Operational Results
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the first quarter ended March 31, 2021 and provided an update on recent progress. “During the...
May 05, 2021 04:30 pm ET
MeiraGTx Announces Participation at Upcoming Investor Conferences
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will participate in multiple conferences in May. BofA...
Apr 19, 2021 04:30 pm ET
MeiraGTx to Present at Chardan 5th Annual Genetic Medicines Manufacturing Summit
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, and Stuart Naylor, Ph.D., chief development officer, will...
Mar 11, 2021 08:00 am ET
MeiraGTx Reports Fourth Quarter and Full Year 2020 Financial and Operational Results
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial and operational results for the fourth quarter and full year ended December 31, 2020 and provided an update on recent...
Mar 04, 2021 08:30 am ET
MeiraGTx to Present at the 2021 Barclays Global Healthcare Conference
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Barclays Global Healthcare Conference on...
Jan 26, 2021 08:30 am ET
MeiraGTx Announces AAV-CNGA3 Granted Fast Track Designation by U.S. FDA for Treatment of Achromatopsia
MeiraGTx Holdings Plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its AAV-CNGA3 gene therapy product candidate...
Dec 16, 2020 04:30 pm ET
MeiraGTx To Present Clinical Program Update for AAV-hAQP1 Treatment of Radiation-Induced Xerostomia
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company will host a webcast and conference call to provide an update on the Company’s AAV-hAQP1 clinical program for the...
Nov 30, 2020 04:30 pm ET
MeiraGTx to Participate in the Evercore ISI 3rd Annual HealthCONx Conference
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Evercore ISI 3rd Annual HealthCONx...
Nov 23, 2020 04:30 pm ET
MeiraGTx to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will participate in a fireside chat at the Piper Sandler 32nd...
Nov 19, 2020 07:00 am ET
MeiraGTx Announces Pricing of Public Offering of Ordinary Shares
MeiraGTx Holdings plc (Nasdaq:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the pricing of an underwritten public offering of 5,000,000 of its ordinary shares at a public offering price of $12.85 per share. In...
Nov 18, 2020 04:24 pm ET
MeiraGTx Announces Proposed Public Offering of Ordinary Shares
MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has commenced an underwritten public offering of 5,000,000 of its ordinary shares. In connection with the offering, MeiraGTx...
Nov 13, 2020 05:55 pm ET
MeiraGTx Announces Investigational Gene Therapy Continues to Demonstrate Statistically Significant Improvement in Vision in Patients with X-Linked Retinitis Pigmentosa One Year After Treatment
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced 12-month data from the ongoing Phase 1/2 clinical trial (NCT03252847) of AAV-RPGR, an investigational gene therapy in development...
Nov 10, 2020 04:30 pm ET
MeiraGTx to Present at the Barclays Gene Editing & Gene Therapy Summit
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Barclays Gene Editing & Gene Therapy...
Nov 05, 2020 08:30 am ET
MeiraGTx Reports Third Quarter 2020 Financial Results
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the third quarter ended September 30, 2020 and provided an update on recent clinical development and business...
Oct 28, 2020 04:30 pm ET
MeiraGTx Announces Data from Ongoing Clinical Trial of AAV-RPGR for the Treatment of X-Linked Retinitis Pigmentosa to be Presented at AAO 2020 Virtual Meeting
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that twelve-month results from the ongoing Phase 1/2 clinical trial (NCT03252847) of AAV-RPGR, an investigational gene therapy for...
Oct 03, 2020 10:50 am ET
MeiraGTx Announces Nine-Month Data from Phase 1/2 Trial of AAV-RPGR Demonstrating Significant and Sustained Vision Improvement in X-Linked Retinitis Pigmentosa (XLRP)
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced nine-month data from the ongoing Phase 1/2 clinical trial (NCT03252847) of AAV-RPGR, an investigational gene therapy in development...
Sep 28, 2020 04:30 pm ET
MeiraGTx to Present at the Chardan 4th Annual Genetic Medicines Conference
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Chardan 4th Annual Genetic Medicines...
Sep 22, 2020 08:30 am ET
MeiraGTx Announces Data from Ongoing Clinical Trial of AAV-RPGR for the Treatment of X-Linked Retinitis Pigmentosa to be Presented at EURETINA 2020 Virtual Meeting
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced nine-month results from the ongoing Phase 1/2 clinical trial (NCT03252847) of AAV-RPGR, an investigational gene therapy for the...
Aug 06, 2020 08:00 am ET
MeiraGTx Reports Second Quarter 2020 Financial Results
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the second quarter ended June 30, 2020 and provided an update on recent clinical development and business...
Aug 05, 2020 08:30 am ET
MeiraGTx Expands Leadership Team with Appointment of Robert K. Zeldin, M.D. as Chief Medical Officer
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Robert K. Zeldin, M.D. as chief medical officer (CMO). A clinical immunologist by training, Dr. Zeldin brings...
Jul 17, 2020 07:30 am ET
MeiraGTx Announces Positive Clinical Data Demonstrating Treatment with AAV-RPGR Investigational Gene Therapy Improves Vision in X-Linked Retinitis Pigmentosa Patients  
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced six-month data from the ongoing Phase 1/2 clinical trial (NCT03252847) of AAV-RPGR, an investigational gene therapy in development...
May 26, 2020 08:30 am ET
MeiraGTx Announces Move to Virtual-Only Format for 2020 Annual General Meeting of Shareholders
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that its 2020 Annual General Meeting of Shareholders scheduled for Tuesday, June 2, 2020 at 10:00 a.m. ET, will be conducted solely...
May 07, 2020 04:30 pm ET
MeiraGTx Reports First Quarter 2020 Financial Results
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the first quarter ended March 31, 2020 and provided an update on recent progress. During the first...
May 06, 2020 04:30 pm ET
MeiraGTx to Present at the Virtual Bank of America Securities 2020 Health Care Conference
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Virtual Bank of America Securities 2020...
Mar 11, 2020 05:00 pm ET
MeiraGTx Reports Full Year 2019 Financial Results
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the full year ended December 31, 2019 and provided an update on recent progress. “During 2019, the MeiraGTx...
Mar 02, 2020 08:30 am ET
MeiraGTx Announces Priority Medicines (PRIME) and Advanced Therapy Medicinal Product (ATMP) Designations Granted by the European Medicines Agency to AAV-RPGR Gene Therapy for the Treatment of X-Linked
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) and Advanced Therapy Medicinal Product (ATMP)...
Feb 24, 2020 04:30 pm ET
MeiraGTx to Present at Upcoming Investor Conferences
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Cowen and Company 40th Annual Health Care...
Dec 05, 2019 04:30 pm ET
MeiraGTx to Host Parkinson’s Disease R&D Day in New York
MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a Parkinson’s disease-focused R&D Day on December 13, 2019 from 9:00-11:30 a.m. ET in New York. The program will focus...
Nov 26, 2019 04:30 pm ET
MeiraGTx to Present at Upcoming Healthcare Conferences
MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Evercore ISI 2nd Annual HealthCONx...
Nov 07, 2019 08:00 am ET
MeiraGTx Reports Third Quarter 2019 Financial Results
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the quarter ended September 30, 2019 and provided an update on recent progress. “Over the course of the third...
Oct 03, 2019 04:45 pm ET
MeiraGTx to Present at Upcoming Scientific and Investor Conferences
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that the Company will present at the following upcoming events: 3rd Annual Chardan Genetic Medicines Conference in New York...
Sep 10, 2019 08:30 am ET
MeiraGTx To Present Clinical Data from Phase 1/2 Trial of AAV-RPE65 at Upcoming Scientific Conferences
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that clinical data updates from the Company’s Phase 1/2 trial of AAV-RPE65 will be presented at two upcoming medical meetings. The...
Aug 08, 2019 06:50 am ET
MeiraGTx Announces Pricing of Public Offering of Ordinary Shares
MeiraGTx Holdings plc (Nasdaq:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the pricing of an underwritten public offering of 3,200,000 of its ordinary shares at a public offering price of $23.50 per share. In...
Aug 07, 2019 04:12 pm ET
MeiraGTx Announces Proposed Public Offering of Ordinary Shares
MeiraGTx Holdings plc (Nasdaq:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has commenced an underwritten public offering of $75 million of its ordinary shares. In connection with the offering,...
Aug 07, 2019 08:00 am ET
MeiraGTx Reports Second Quarter 2019 Financial Results and Provides Corporate Update
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the quarter ended June 30, 2019 and provided an update on recent clinical progress. MeiraGTx today announced...
May 14, 2019 08:00 am ET
MeiraGTx Reports First Quarter 2019 Financial Results and Provides Corporate Update
MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the quarter ended March 31, 2019 and provided a corporate update. MeiraGTx today reported positive topline...
May 14, 2019 07:30 am ET
MeiraGTx Announces Positive 6-Month Data from Phase 1/2 Trial of Investigational Gene Therapy AAV-RPE65 for RPE65-Deficiency
MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced positive data from a Phase 1/2 dose escalation trial of AAV-RPE65, the Company’s investigational gene therapy for the treatment of...
May 10, 2019 08:30 am ET
MeiraGTx Appoints Nicole Seligman to Board of Directors
MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Nicole Seligman to its Board of Directors. Ms. Seligman is an accomplished leader with extensive executive, legal,...
May 06, 2019 04:30 pm ET
MeiraGTx to Present at Bank of America Merrill Lynch Healthcare Conference
MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the BAML Healthcare Conference on Wednesday,...
Apr 25, 2019 04:30 pm ET
MeiraGTx Announces Upcoming Presentation on Achromatopsia Gene Therapy Candidate AAV-CNGA3 at ARVO 2019
MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced a pre-clinical poster on safety and efficacy of the Company’s gene therapy product candidate AAV-CNGA3 for the treatment of patients...
Mar 26, 2019 04:05 pm ET
MeiraGTx Reports Full Year 2018 Financial Results
MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the fourth quarter and full year ended December 31, 2018. “2018 was a transformative year for MeiraGTx with us...
Mar 06, 2019 04:30 pm ET
MeiraGTx to Present at the Barclays Global Healthcare Conference
MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Barclays Global Healthcare Conference on...
Feb 27, 2019 08:15 am ET
MeiraGTx Announces $80 Million Private Placement of Ordinary Shares
MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has agreed to sell approximately 5.8 million ordinary shares at a price of $13.80 per share. MeiraGTx anticipates aggregate...
Feb 21, 2019 04:30 pm ET
MeiraGTx Appoints Martin Indyk, Ph.D. to Board of Directors
MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Dr. Martin Indyk to its Board of Directors. Martin Indyk is an American diplomat who has served in senior...
Feb 05, 2019 08:30 am ET
MeiraGTx to Present at the BIO CEO & Investor Conference
MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx, will present at the BIO CEO & Investor Conference...
Jan 31, 2019 06:30 am ET
MeiraGTx Enters into Strategic Collaboration with Janssen to Develop and Commercialize Gene Therapy Treatments for Inherited Retinal Diseases
MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has entered into a broad strategic collaboration with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen...
Jan 31, 2019 05:30 am ET
Janssen Enters Worldwide Collaboration and License Agreement with MeiraGTx to Develop Gene Therapy Programs for Inherited Retinal Diseases
RARITAN, N.J., Jan. 31, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a worldwide collaboration and license agreement with MeiraGTx Holdings plc (NASDAQ: MGTX), a clinical-stage gene therapy company, to develop, manufacture and commercialize its clinical stage inherited retinal disease portfolio, including leading product candidates for achromatopsia (ACHM) caused by mutations in either CNGB3 or CNGA3, and X-linked retinitis pigmentosa (XLRP). Further, the companies have formed a research collaboration to explore new targets for other inhe
Jan 02, 2019 08:30 am ET
MeiraGTx to Present at the 37th Annual J.P. Morgan Healthcare Conference
MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx, will present at the J.P. Morgan 37th Annual...
Dec 12, 2018 08:30 am ET
MeiraGTx Announces Publication of New Research Identifying Underlying Mechanism of Functional Improvement Seen with AAV-GAD Gene Therapy in Parkinson’s Disease
MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced publication of research assessing the mechanism underlying the motor improvement observed in patients with Parkinson’s disease who...
Nov 08, 2018 08:30 am ET
MeiraGTx Reports Third Quarter 2018 Financial Results and Provides Corporate Update
MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the third quarter of 2018 and provided a corporate update. “The third quarter was very productive for...
Oct 31, 2018 08:30 am ET
MeiraGTx Announces Exclusive Licensing Agreement with National Institutes of Health for Gene Therapy Treatment for Sjögren’s Syndrome and Associated Xerostomia or Xerophthalmia
MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced an exclusive licensing agreement with the National Institute of Dental and Craniofacial Research (NIDCR), a division of the National...
Oct 25, 2018 08:30 am ET
MeiraGTx Expands Leadership Team with Appointment of Katherine Breedis as Chief Financial Officer
MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage gene therapy company, today announced that on October 2nd, 2018, it expanded its leadership team with the appointment of Katherine Breedis as chief financial officer....
Oct 16, 2018 08:00 am ET
MeiraGTx Enters Collaboration with Johnson & Johnson Innovation to Develop Regulatable Gene Therapy Treatment using MeiraGTx Riboswitch Technology
MeiraGTx Holdings Plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has entered into a research collaboration and evaluation agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the...
Oct 09, 2018 07:00 am ET
MeiraGTx Announces Acquisition of Vector Neurosciences, Gains Phase 2 Gene Therapy Program for Parkinson’s Disease
MeiraGTx Holdings Plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has acquired Vector Neurosciences Inc. (“Vector”) in an all-stock transaction. As a result of the acquisition, which was...
Oct 02, 2018 04:30 pm ET
MeiraGTx to Present at Upcoming Conferences
MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it will present at the following conferences: 2018 Cell Gene Meeting on the Mesa on Thursday, October 4, 2018 at 1:45 p.m. PT...
Aug 27, 2018 08:00 am ET
MeiraGTx Announces AAV-CNGA3 Granted Rare Pediatric Disease Designation by the U.S. FDA for the Treatment of Achromatopsia
MeiraGTx Holdings Plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that the Offices of Orphan Products Development and Pediatric Therapeutics of the U.S. Food and Drug Administration (FDA) have...
Aug 20, 2018 08:00 am ET
MeiraGTx Announces AAV-CNGB3 Granted Fast Track Designation by U.S. FDA for Treatment of Achromatopsia
MeiraGTx Holdings Plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its AAV-CNGB3 gene therapy product candidate...
Aug 13, 2018 07:00 am ET
MeiraGTx Announces AAV-CNGA3 Has Received Orphan Drug Designation from the U.S. FDA for the Treatment of Achromatopsia
MeiraGTx Holdings Plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for its AAV-CNGA3 gene therapy product...
Aug 08, 2018 08:00 am ET
MeiraGTx Reports Second Quarter 2018 Financial Results and Provides Corporate Update
MeiraGTx Holdings Plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the second quarter of 2018 and provided a corporate update. “This has been an important year and an exciting...
Jun 26, 2018 08:00 am ET
MeiraGTx Receives Positive Opinion for Orphan Drug Designation in the European Union for AAV-CNGA3 for the Treatment of Achromatopsia
MeiraGTx Holdings plc (Nasdaq:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products issued a positive opinion recommending orphan...
Jun 21, 2018 08:00 am ET
MeiraGTx Announces MHRA Grants MIA (IMP) License for cGMP Manufacturing Facility in London, UK
MeiraGTx Holdings Plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced it has been granted a Manufacturer’s Authorization for Investigational Medicinal Products from the United Kingdom’s Medicines and...
Jun 12, 2018 05:44 pm ET
MeiraGTx Announces Closing of Initial Public Offering
MeiraGTx Holdings plc (Nasdaq:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the closing of its initial public offering of 5,000,000 ordinary shares at a public offering price of $15.00 per share. The gross...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.